StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Atripla (efavirenz / FTC / TDF by Quarter

Atripla (efavirenz / FTC / TDF — legacy breakout) ($M) ($M)

QuarterlyAnnual

Gilead Sciences Atripla (efavirenz / FTC / TDF: $27M in Q4 2021, down 28.9% from a year earlier. That is the lowest of the 21 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2021
27
Period ended Dec 31, 2021
Change on a year earlier
-28.9%
38 in Q4 2020
History
21 quarters
Since Q4 2016
Sources
14
Documents cited below

Where the Q4 2021 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2022-02-23) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAtripla (efavirenz / FTC / TDF — legacy breakout) ($M) ($M)Year on yearSource
Q4 2021Dec 31, 202127-28.9%Form 10-K (filed 2022-02-23) ↗
Q3 2021Sep 30, 202127-76.1%Form 10-Q (filed 2021-11-03) ↗
Q2 2021Jun 30, 202160-41.7%Form 10-Q (filed 2021-08-05) ↗
Q1 2021Mar 31, 202131-67.4%Form 10-Q (filed 2021-05-06) ↗
Q4 2020Dec 31, 202038-70.3%Form 10-K (filed 2022-02-23) ↗
Q3 2020Sep 30, 2020113-24.2%Form 10-Q (filed 2021-11-03) ↗
Q2 2020Jun 30, 2020103-32.2%Form 10-Q (filed 2021-08-05) ↗
Q1 2020Mar 31, 202095-44.4%Form 10-Q (filed 2020-05-06) ↗
Q4 2019Dec 31, 2019128-55.1%Form 10-K (filed 2022-02-23) ↗
Q3 2019Sep 30, 2019149-42.2%Form 10-Q (filed 2019-11-05) ↗
Q2 2019Jun 30, 2019152-56.4%Form 10-Q (filed 2019-08-06) ↗
Q1 2019Mar 31, 2019171-45.5%Form 10-Q (filed 2020-05-06) ↗
Q4 2018Dec 31, 2018285-35.2%Form 10-K (filed 2021-02-25) ↗
Q3 2018Sep 30, 2018258-41.2%Form 10-Q (filed 2019-11-05) ↗
Q2 2018Jun 30, 2018349-26.5%Form 10-Q (filed 2019-08-06) ↗
Q1 2018Mar 31, 2018314-30.5%Form 10-Q (filed 2019-05-08) ↗

Breakdown

What makes up atripla (efavirenz / FTC / TDF

Cite this data

StockData. (2026). Gilead Sciences Atripla (efavirenz / FTC / TDF ($M), quarterly Q4 2016–Q4 2021 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv-atripla

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.